28/01/2015 23:29:15 Free Membership Login

Neurocrine Biosciences News (NASDAQ:NBIX)

DateTimeSource
Headline
01/20/20158:00AMPRNUSNeurocrine Biosciences Announces Oral Presentation of NBI-77860 Clinical Trial Data in Classic Congenital Adrenal Hyperplasia...
Neurocrine Biosciences Announces Oral Presentation of NBI-77860 Clinical Trial Data in Classic Congenital Adrenal Hyperplasia at ENDO 2015 PR Newswire SAN DIEGO, Jan. 20, 2015 SAN DIEGO, Jan. 20, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the steering committee of ENDO 2015 has... More...>>
01/16/20152:30PMPRNUSNeurocrine Biosciences Announces Granting of Orphan Drug Status for NBI-77860 in Congenital Adrenal Hyperplasia
Neurocrine Biosciences Announces Granting of Orphan Drug Status for NBI-77860 in Congenital Adrenal Hyperplasia PR Newswire SAN DIEGO, Jan. 16, 2015 SAN DIEGO, Jan. 16, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF... More...>>
01/08/20151:00PMPRNUSNeurocrine Biosciences to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Neurocrine Biosciences to Present at the 33rd Annual J.P. Morgan Healthcare Conference Live Audio Webcast will be on January 15, 2015 PR Newswire SAN DIEGO, Jan. 8, 2015 SAN DIEGO, Jan. 8, 2015 /PRNewswire/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer... More...>>
01/08/20158:00AMPRNUSAbbVie Announces Positive Top-Line Results From Phase 3 Study of Investigational Medicine Elagolix in Patients with Endometri...
AbbVie Announces Positive Top-Line Results From Phase 3 Study of Investigational Medicine Elagolix in Patients with Endometriosis - Study meets co-primary efficacy endpoints; results show treatment with elagolix reduces endometriosis-associated pain (dysmenorrhea and non-menstrual pelvic pain) compared to placebo - Results... More...>>
12/10/20148:00AMPRNUSNeurocrine Biosciences Announces Expansion of its Clinical Pipeline
Neurocrine Biosciences Announces Expansion of its Clinical Pipeline Phase I/II Clinical Trial of CRF Antagonist in Adolescent Females with Classic Congenital Adrenal Hyperplasia Initial Pilot Clinical Study Demonstrated Profound Impact on Key Biomarkers PR Newswire SAN DIEGO, Dec. 10, 2014 SAN DIEGO, Dec. 10, 2014 /PRNewswire/... More...>>
12/04/20147:00PMPRNUSNeurocrine Biosciences to Present at the 25th Annual Oppenheimer Healthcare Conference
Neurocrine Biosciences to Present at the 25th Annual Oppenheimer Healthcare Conference Live Audio Webcast will be on December 10, 2014 PR Newswire SAN DIEGO, Dec. 4, 2014 SAN DIEGO, Dec. 4, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive... More...>>
11/25/20141:00PMPRNUSNeurocrine to Present at the 2014 Deutsche Bank BioFEST and the 26th Annual Piper Jaffray Healthcare Conference
Neurocrine to Present at the 2014 Deutsche Bank BioFEST and the 26th Annual Piper Jaffray Healthcare Conference Live Audio Webcasts will be on December 2nd and 3rd, 2014 PR Newswire SAN DIEGO, Nov. 25, 2014 SAN DIEGO, Nov. 25, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin... More...>>
11/12/20141:56PMPRNUSNeurocrine Biosciences to Present at the Jefferies 2014 Global Healthcare Conference
Neurocrine Biosciences to Present at the Jefferies 2014 Global Healthcare Conference Live Audio Webcast will be on November 19, 2014 PR Newswire SAN DIEGO, Nov. 12, 2014 SAN DIEGO, Nov. 12, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive... More...>>
11/12/20141:00PMPRNUSNeurocrine Biosciences to Present at the Jefferies 2014 Global Healthcare Conference
Neurocrine Biosciences to Present at the Jefferies 2014 Global Healthcare Conference Live Audio Webcast will be on November 19, 2014 PR Newswire SAN DIEGO, Nov. 12, 2014 SAN DIEGO, Nov. 12, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive... More...>>
11/04/20147:30AMPRNUSNeurocrine Biosciences, Inc. Announces Appointment of Darin Lippoldt as Chief Legal Officer
Neurocrine Biosciences, Inc. Announces Appointment of Darin Lippoldt as Chief Legal Officer PR Newswire SAN DIEGO, Nov. 4, 2014 SAN DIEGO, Nov. 4, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Darin Lippoldt has joined the executive management team as Chief Legal Officer. "We are... More...>>
11/03/20147:00PMPRNUSNeurocrine Biosciences to Present at the Nomura Biotechnology Conference
Neurocrine Biosciences to Present at the Nomura Biotechnology Conference Live Audio Webcast will be on November 6, 2014 PR Newswire SAN DIEGO, Nov. 3, 2014 SAN DIEGO, Nov. 3, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine... More...>>
11/03/20144:01PMPRNUSNeurocrine Biosciences Reports Third Quarter 2014 Results
Neurocrine Biosciences Reports Third Quarter 2014 Results NBI-98854 Phase III Program Underway for Tardive Dyskinesia Tourette Syndrome Phase IB Study Initiated FDA Grants Breakthrough Therapy Designation for Tardive Dyskinesia PR Newswire SAN DIEGO, Nov. 3, 2014 SAN DIEGO, Nov. 3, 2014 /PRNewswire/ -- Neurocrine Biosciences... More...>>
10/30/20147:30AMPRNUSNeurocrine Biosciences Receives Breakthrough Therapy Designation for NBI-98854 in Tardive Dyskinesia
Neurocrine Biosciences Receives Breakthrough Therapy Designation for NBI-98854 in Tardive Dyskinesia PR Newswire SAN DIEGO, Oct. 30, 2014 SAN DIEGO, Oct. 30, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy... More...>>
10/27/20144:05PMPRNUSNeurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2014 Financial Results
Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2014 Financial Results Conference Call and Webcast Scheduled for Monday, November 3, 2014 PR Newswire SAN DIEGO, Oct. 27, 2014 SAN DIEGO, Oct. 27, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the... More...>>
10/20/20144:05PMPRNUSNeurocrine Announces Initiation Of Phase III Study For VMAT2 Inhibitor NBI-98854
Neurocrine Announces Initiation Of Phase III Study For VMAT2 Inhibitor NBI-98854 PR Newswire SAN DIEGO, Oct. 20, 2014 SAN DIEGO, Oct. 20, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase III clinical trial (Kinect 3 Study) of its proprietary Vesicular Monoamine... More...>>
10/02/20144:02PMPRNUSNeurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study
Neurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study NBI-98854 TO BE EVALUATED FOR BOTH CHILDREN AND ADOLESCENTS IN T-FORCE CLINICAL TRIAL PR Newswire SAN DIEGO, Oct. 2, 2014 SAN DIEGO, Oct. 2, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced... More...>>
10/01/20145:20PMPRNUSNeurocrine Biosciences, Inc. Announces Appointment of Malcolm Lloyd-Smith as Chief Regulatory Officer
Neurocrine Biosciences, Inc. Announces Appointment of Malcolm Lloyd-Smith as Chief Regulatory Officer PR Newswire SAN DIEGO, Oct. 1, 2014 SAN DIEGO, Oct. 1, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Malcolm Lloyd-Smith has joined the executive management team as Chief Regulatory... More...>>
09/03/20141:00PMPRNUSNeurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference Live Audio Webcast will be on September 10, 2014 PR Newswire SAN DIEGO, Sept. 3, 2014 SAN DIEGO, Sept. 3, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive... More...>>
08/06/20144:02PMPRNUSNeurocrine Biosciences Reports Second Quarter 2014 Results
Neurocrine Biosciences Reports Second Quarter 2014 Results SUCCESSFUL END-OF-PHASE II MEETING FOR NBI-98854 IN TARDIVE DYSKINESIA TOURETTE SYNDROME IND FOR NBI-98854 TO BE FILED THIS MONTH PR Newswire SAN DIEGO, Aug. 6, 2014 SAN DIEGO, Aug. 6, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced... More...>>
07/29/201410:00AMPRNUSNeurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results
Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results Earnings Release After Close of Market, Wednesday, August 6, 2014 Conference Call and Webcast Scheduled For Thursday, August 7, 2014 PR Newswire SAN DIEGO, July 29, 2014 SAN DIEGO, July 29, 2014 /PRNewswire/ -- Neurocrine... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq nbix150128 23:29